Radiodermatitis - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 41 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiodermatitis - Pipeline Review, H2 2016, provides an overview of the Radiodermatitis (Dermatology) pipeline landscape.

Radiodermatitis is an inflammation of the skin caused by radiation. Several factors can be attributed to the varying response of patients' skin to radiation therapy such as treatment-related factors such as individual fraction size, type of energy, and the use of bolus doses can impact skin reactions. Host factors also may play a role in the development of radiodermatitis; they include genetic factors, personal factors, existing skin integrity issues, comorbid conditions, nutritional status, age, race and ethnicity, medications, sun exposure, smoking, and mobility.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Radiodermatitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Radiodermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiodermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Radiodermatitis.

Radiodermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Radiodermatitis (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Radiodermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Radiodermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Radiodermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Radiodermatitis (Dermatology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Radiodermatitis (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Radiodermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Radiodermatitis Overview 6
Therapeutics Development 7
Pipeline Products for Radiodermatitis - Overview 7
Pipeline Products for Radiodermatitis - Comparative Analysis 8
Radiodermatitis - Therapeutics under Development by Companies 9
Radiodermatitis - Therapeutics under Investigation by Universities/Institutes 10
Radiodermatitis - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Radiodermatitis - Products under Development by Companies 13
Radiodermatitis - Products under Investigation by Universities/Institutes 14
Radiodermatitis - Companies Involved in Therapeutics Development 15
Reata Pharmaceuticals, Inc. 15
SK Chemicals Co., Ltd. 16
viDA Therapeutics Inc 17
Radiodermatitis - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
cerium oxide - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Drug to Antagonize Adenosine A2A Receptor for Radiation Dermatitis - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
omaveloxolone - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
SKI-2162 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
ST-266 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
VTI-1000 Series - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Radiodermatitis - Dormant Projects 36
Radiodermatitis - Discontinued Products 37
Radiodermatitis - Product Development Milestones 38
Featured News & Press Releases 38
Jul 25, 2014: Reata Enrolls First Patient in the PRIMROSE Study, a Phase 2 Study Examining RTA 408 in Breast Cancer Patients at Risk for Radiation Dermatitis 38
Apr 24, 2014: RTA 408 Lotion Demonstrates Favorable Safety and Pharmacodynamic Response in a Phase 1 Study 38
Apr 10, 2014: Preclinical Study of Reata's RTA 408 Demonstrates Role in Prevention and Treatment of Radiation Dermatitis 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 40
Disclaimer 41

List of Tables

Number of Products under Development for Radiodermatitis, H2 2016 7
Number of Products under Development for Radiodermatitis - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Radiodermatitis - Pipeline by Reata Pharmaceuticals, Inc., H2 2016 15
Radiodermatitis - Pipeline by SK Chemicals Co., Ltd., H2 2016 16
Radiodermatitis - Pipeline by viDA Therapeutics Inc, H2 2016 17
Assessment by Monotherapy Products, H2 2016 18
Number of Products by Stage and Target, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 26
Radiodermatitis - Dormant Projects, H2 2016 36
Radiodermatitis - Discontinued Products, H2 2016 37